Merck’s Keytruda Meets its Primary Endpoint in the P-III Trial (KEYNOTE-A18) for Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Shots:
- The P-III trial (KEYNOTE-A18) evaluating Keytruda + EBRT followed by brachytherapy and CT vs PBO + chemoradiotherapy in 980 patients with newly diagnosed high-risk LA cervical cancer. The trial was sponsored by Merck and conducted in collaboration with the European Network for Gynaecological Oncology Trial groups and the GOG Foundation, Inc.
- The trial met its 1EPs of PFS and showed a significant & clinical improvement in PFS at a prespecified interim analysis conducted by IDMC, a favorable trend in OS was also observed
- The safety profile was consistent with prior reported studies with no new safety signals & the results will be submitted to regulatory authorities
Ref: Merck | Image: Merck
Related News:- Merck Reports the US FDA Acceptance of sBLA for Keytruda (pembrolizumab) to Treat Advanced or Unresectable Biliary Tract Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
